Patent ID: 8150627

Claim:
A method for identifying differentially methylated genomic CpG dinucleotide sequences associated with adenocarcinoma in an individual, said method comprising: (a) obtaining a biological sample comprising genomic DNA from said individual; (b) measuring the level of methylation in said biological sample at a CpG dinucleotide sequence in two or more genomic targets designated as SEQ ID NOS: 59, 293, 354, 373, 1556-1578, 1580-1604 or 1606-1609 in said sample, and (c) comparing the levels of methylation at said genomic CpG dinucleotide sequences in the biological sample to a reference level of methylation of said genomic CpG dinucleotide sequences, wherein said reference level comprises the level of methylation at said genomic CpG dinucleotide sequences in a normal sample, wherein an increase in the level of methylation of said genomic CpG dinucleotide sequences in the biological sample for the genomic targets designated as SEQ ID NOS: 293, 354, 1557-1561, 1563-1567, 1569-1578, 1580-1583, 1585-1598, 1600-1604 or 1607-1609, or a decrease in the level of methylation of said genomic CpG dinucleotide sequences in the biological sample for the genomic targets designated as SEQ ID NOS: 59, 373, 1556, 1562, 1568, 1584, 1599 or 1606, compared to the reference level identifies differentially methylated genomic CpG dinucleotide sequences associated with adenocarcinoma in said individual.